Boehringer biopharmaceuticals China receives approval supply EU and US
Boehringer Ingelheim Biopharmaceuticals China receives approval for supply of EU and US markets
Search
C3-binding polypeptide
C3-binding polypeptide
BI 764532
DLL3/CD3 T-cell engager
BI 764532
DLL3/CD3 T-cell engager
BI 764532
DLL3/CD3 T-cell engager: DLL3/CD3 T-cell engager
Fabio Paganini fostering inclusion & agility in AH
How employees are contributing to an inclusive culture at Boehringer Ingelheim.
Bees and biodiversity
At Boehringer Ingelheim we attach great importance to sustainable planting on our company site – and to protecting the bees.
Microbial expertise
Microbial systems are ideal for synthesizing smaller and non-glycosylated proteins, complementing mammalian cell processes for larger proteins like monoclonal antibodies.
Biberach
The largest research and development center of Boehringer Ingelheim is located in Biberach, Germany.
International recognition for Boehringer Ingelheim BioXcellence™
International recognition for Boehringer Ingelheim BioXcellence™
Awards & International Recognition| Bioxcellence | Boehringer Ingelheim
Explore Bioxcellence's global recognition, showcasing our prestigious awards & certifications. Witness our commitment to excellence in biopharmaceuticals!
Boehringer Ingelheim Venture Fund invests precision antimicrobials
Boehringer Ingelheim Venture Fund invests in the development of precision antimicrobials
Biopharmaceuticals: large molecules, enormous potential
Researching, developing and manufacturing biopharmaceuticals is a highly complex and lengthy process, but it has enormous potential.
Plasmid DNA Production | BioXcellence
Discover our range of plasmid DNA production solutions from research to GMP.
biologicals-development-center
Europe’s largest biotechnology center in Biberach, Germany is the home to three development units.
Animal Welfare through environmental sustainability
Producing honey and contributing to environmental sustainability during your work hours.
China pioneers biosecurity report against ASF
Boehringer Ingelheim compiles data from 1,000 swine farms into the first market report on biosecurity. Document sheds light on livestock management and contributes to the fight against African swine fever.
Cancer's Big 4
We have a robust pipeline of clinical assets including cancer cell-directed therapies, for which we are investigating the key drivers of cancer such as P53 and KRAS.
Combination Therapy
It’s the smart combination of our cancer cell-directed and immuno-oncology approaches that may offer the greatest benefit for people living with cancer.
Global Computational Biology & Digital Sciences
Discover how we play a vital role in identifying new drugs and how our work results in breakthrough therapies.
Biostatistics & Data Science
Discover how we use data science methods on clinical trials data to develop patient-led innovations and breakthrough treatments.
Global mobility
We are a global company with a global outlook. We welcome the breadth of perspective that international experience brings to our teams.
The Core of our Leitbild
Who we are and what we strive for
Serbia
Serbia
sustainably fighting rabies info hub
Did you know that every nine minutes, rabies takes a human life? Find out how we support the elimination of this deadly disease.